ALS Association USA Research Feed

Subscribe to this feed at http://www.alsa.org/rss/default.cfm

RSS is a free service offered by The ALS Association for non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You must use the RSS feeds as provided by The ALS Association, and you may not edit or modify the text, content or links supplied by The ALS Association. For web posting, reprint, transcript or licensing requests for ALS Association material, please send your request to webmaster@alsa.org.

The ALS Association Announces New Research Grants
The ALS Association is proud to announce seven new research grants that will allow scientists to study several of topics pertinent to The Association's TREAT ALS Research Portfolio.

Drug Company Working Group Meeting Attracts Professionals from Academia and Industry to Discuss Therapeutic Opportunities for ALS
The ALS Association brought together an overflow crowd of individuals with the common purpose of finding new ALS treatments at The American Academy of Neurology Annual Meeting.

ALS Drug Discovery Meeting Forges Partnerships for Faster Drug Development
In early March, more than 120 researchers, drug developers and government officials collaborated to discuss ways to accelerate drug discovery to treat ALS.

The Search for Biomarkers to Speed Drug Discovery
No description available

Potential New Targets in the Search for Therapy
No description available

The Current State of Clinical Trials in ALS
No description available

Request for Proposals - Clinical Management and Research
Two open calls for proposals: Clinical Research Pilot Study and Clinical Management Grants. Deadline for brief study outline is May 28, 2012.

Quest Diagnostics Announces C9orf72 Genetic Test for ALS
The company's Athena Diagnostics business unit unveiled the new test at the American Academy of Neurology Annual Meeting this week in New Orleans.

Cytokinetics Announces Encouraging Results from CK-2017357 Phase II Clinical Trials
As reported at the 64th annual meeting of the American Academy of Neurology, Cytokinetics' drug CK-2017357 has been shown to be safe and well-tolerated at different dosage levels when used alone or in combination with riluzole.

2012 Sheila Essey Award Recipient Recognized at American Academy of Neurology Conference
A clinician scientist with a strong background in molecular cell biology received the prestigious award for ALS research on April 24.

Receive our RSS feed

Subscribe to email updates